Literature DB >> 15198212

Objective determination of pelvic movement during hind limb lameness by use of a signal decomposition method and pelvic height differences.

Joanne Kramer1, Kevin G Keegan, Gal Kelmer, David A Wilson.   

Abstract

OBJECTIVE: To evaluate pelvic movement over a large number of strides in sound horses and in horses with induced hind limb lameness by applying methods to the pelvis that have been described for evaluating vertical head movement in horses with induced forelimb lameness. ANIMALS: 17 adult horses. PROCEDURE: Horses were filmed while trotting on a treadmill before and after induction of transient mild and moderate hind limb lamenesses. Vertical pelvic movement was measured by a signal decomposition method. The vertical pelvic signal was decomposed into a periodic component (A1) that occurred at half the stride frequency (representing vertical pelvic movement caused by lameness) and another periodic component (A2) that occurred at stride frequency (representing normal vertical pelvic movement of a trotting horse). Vertical pelvic and foot positions were correlated for each stride to compare the difference between the minimum and maximum heights of the pelvis during and after stance of the right hind limb to the minimum and maximum heights of the pelvis during and after stance of the left hind limb.
RESULTS: Maximum pelvic height difference and lameness amplitude (A1) differed significantly between sound and mild or moderate hind limb lameness conditions. Mean A1 value for vertical pelvic movement in sound horses was less than that previously reported for vertical head movement. CONCLUSION AND CLINICAL RELEVANCE: Pelvic height differences and signal decomposition of pelvic movement can be used to objectively evaluate hind limb lameness in horses over a large number of strides in clinical and research settings.

Entities:  

Mesh:

Year:  2004        PMID: 15198212     DOI: 10.2460/ajvr.2004.65.741

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  7 in total

1.  Head and pelvic movement asymmetry during lungeing in horses with symmetrical movement on the straight.

Authors:  M Rhodin; L Roepstorff; A French; K G Keegan; T Pfau; A Egenvall
Journal:  Equine Vet J       Date:  2015-05-29       Impact factor: 2.888

2.  Head, withers and pelvic movement asymmetry and their relative timing in trot in racing Thoroughbreds in training.

Authors:  T Pfau; K Noordwijk; M F Sepulveda Caviedes; E Persson-Sjodin; A Barstow; B Forbes; M Rhodin
Journal:  Equine Vet J       Date:  2017-07-03       Impact factor: 2.888

3.  Effect of a unilateral hind limb orthotic lift on upper body movement symmetry in the trotting horse.

Authors:  Jodi Vertz; Diana Deblanc; Marie Rhodin; Thilo Pfau
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

4.  Vertical movement symmetry of the withers in horses with induced forelimb and hindlimb lameness at trot.

Authors:  M Rhodin; E Persson-Sjodin; A Egenvall; F M Serra Bragança; T Pfau; L Roepstorff; M A Weishaupt; M H Thomsen; P R van Weeren; E Hernlund
Journal:  Equine Vet J       Date:  2018-05-17       Impact factor: 2.888

5.  Lateral movement of the saddle relative to the equine spine in rising and sitting trot on a treadmill.

Authors:  A Byström; L Roepstorff; M Rhodin; F Serra Bragança; M T Engell; E Hernlund; E Persson-Sjödin; R van Weeren; M A Weishaupt; A Egenvall
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

6.  Effect of meloxicam treatment on movement asymmetry in riding horses in training.

Authors:  Emma Persson-Sjodin; Elin Hernlund; Thilo Pfau; Pia Haubro Andersen; Karin Holm Forsström; Marie Rhodin
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

7.  Variation in gait parameters used for objective lameness assessment in sound horses at the trot on the straight line and the lunge.

Authors:  A M Hardeman; F M Serra Bragança; J H Swagemakers; P R van Weeren; L Roepstorff
Journal:  Equine Vet J       Date:  2019-02-12       Impact factor: 2.888

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.